A meta-analysis found that abaloparatide increased bone density at the femoral neck and total hip more than teriparatide in postmenopausal women with osteoporosis, with 51% less hypercalcemia.
51% less hypercalcemiaAbaloparatide caused roughly half the rate of high calcium levels compared to teriparatide, a clinically meaningful safety difference
What the researchers found
In a meta-analysis of four studies (16 subgroups) from head-to-head RCTs, abaloparatide showed significantly greater BMD improvements than teriparatide at the femoral neck (WMD = 1.58, 95% CI 0.52–2.63) and total hip (WMD = 1.46, 95% CI 0.59–2.32) — both rated high-quality evidence by GRADE criteria.
All BMD parameters at 24 weeks favored abaloparatide except lumbar spine. The incidence of hypercalcemia was 51% lower with abaloparatide compared to teriparatide. No significant differences were found in serious adverse events or deaths between the two drugs. However, compared to placebo, abaloparatide was associated with higher risks of nausea and palpitations. Fracture data was insufficient for meaningful analysis.
Why it matters
For the millions of postmenopausal women with osteoporosis, choosing between the two available bone-building peptide drugs has been difficult due to limited head-to-head data. This meta-analysis provides the most comprehensive comparison to date, suggesting abaloparatide may offer an edge at the hip — the most clinically important fracture site — while also being associated with less hypercalcemia, a meaningful safety advantage.
How the study worked
Systematic review and meta-analysis searching Medline, Embase, Web of Science, Cochrane, and ClinicalTrials.gov through September 2022. Only randomized controlled trials with direct head-to-head comparisons of abaloparatide vs teriparatide were included. Evidence quality was assessed using the GRADE framework. Outcomes included BMD change from baseline and adverse event rates.
What this study cannot tell us
Only four studies met inclusion criteria, all from manufacturer-sponsored trials, which introduces potential bias. Fracture data was insufficient for analysis — and fracture prevention, not BMD alone, is the ultimate clinical outcome. The meta-analysis was limited to postmenopausal women, so results may not apply to men or premenopausal osteoporosis. Most comparisons relied on post hoc analyses of RCTs rather than pre-specified head-to-head designs.
How to read the evidence
This is a meta-analysis of RCTs — generally high-level evidence. The GRADE framework rated the femoral neck and total hip results as high quality. However, the small number of included studies (4), manufacturer sponsorship, and insufficient fracture data limit the overall strength somewhat.
When this study was published
Published in 2023 with a search through September 2022, this is a recent and up-to-date meta-analysis. It represents the current best evidence for comparing these two peptide osteoporosis drugs.
The bigger picture
Both abaloparatide and teriparatide are peptide analogs related to parathyroid hormone that stimulate bone formation — a fundamentally different approach from antiresorptive drugs like bisphosphonates that only slow bone loss. This meta-analysis helps clinicians differentiate between the two anabolic options, particularly for patients at high risk of hip fractures where abaloparatide's advantage appears most pronounced.
Questions still open
- Does abaloparatide's greater BMD improvement at the hip translate into fewer actual hip fractures compared to teriparatide?
- Why does abaloparatide appear more effective at the hip but not the lumbar spine, given both drugs target the same PTH1 receptor?
- Would longer treatment durations (beyond 24 weeks) maintain or widen the gap between these two drugs?
Common questions
What's the difference between abaloparatide and teriparatide?
Should I switch from teriparatide to abaloparatide based on this study?
Read the original research
Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.
Journal of orthopaedic surgery and research, 18(1), 116
Citation
Hong, Pan; Liu, Ruikang; Rai, Saroj; Liu, JiaJia; Zhou, YeMing; Zheng, Yu; Li, Jin. (2023). Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.. Journal of orthopaedic surgery and research, 18(1), 116. https://doi.org/10.1186/s13018-023-03595-x